Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer

NCT00126607 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

35

Enrollment

NIH

Sponsor class

Stopped Poor accrual.

Conditions

High-grade Salivary Gland Mucoepidermoid Carcinoma
Recurrent Salivary Gland Cancer
Salivary Gland Acinic Cell Tumor
Salivary Gland Adenocarcinoma
Salivary Gland Poorly Differentiated Carcinoma
Stage IVA Salivary Gland Cancer
Stage IVB Salivary Gland Cancer
Stage IVC Salivary Gland Cancer

Interventions

BIOLOGICAL: trastuzumab
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)